RCS - OptiBiotix Health - SweetBiotix® Sampling

OptiBiotix HealthAnnouncement

Thu 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260514:nRSN2407Ea&default-theme=true

RNS Number : 2407E  OptiBiotix Health PLC  14 May 2026

OptiBiotix Health plc

("OptiBiotix" or the "Company" or "the Group")

 

SweetBiotix® Sampling

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), a life sciences business
developing products which reduce hunger and food cravings, enhance the gut
microbiome, and sweet fibres as healthy sugar substitutes announces plans to
demonstrate its SweetBiotix products to shareholders.

 

The Company reported a breakthrough in the manufacture of its SweetBiotix
products on 24 November 2025 leading to higher yields of purer, more
concentrated, better tasting product with lower ingredient and production
costs.

 

The Company is now in a position to demonstrate this product to shareholders
at an event in London to be held in June 2026, subject to the availability of
a suitable venue.  In order to assess attendance and venue size, the Company
would encourage all existing shareholders and prospective investors who are
interested in attending to sign up (it should take less than one minute) using
the link below:-

 

1.    Visit https://optibiotix.com/s/3eda67
(https://optibiotix.com/s/3eda67)

2.    Follow the prompts on the top right hand side of the website marked
SIGN UP

3.    Complete your account profile (name/email address)

 

Once registered, OptiBiotix can update investors on location and timings and
send invitations to interested shareholders.  The meeting will give an
overview of the commercial progress of the Company's first generation products
, second generation products and their route to market, and sampling of
SweetBiotix.

 

 

 For further information, please contact: OptiBiotix Health plc      www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman
 Stephen O'Hara, Chief Executive

About OptiBiotix  :  www.optibiotix.com (http://www.optibiotix.com)

OptiBiotix Health plc (AIM: OPTI, OTCQB: OPTBF), OptiBiotix Health has
developed a range of technologies and commercialised products which modulate
the human microbiome to help prevent and manage human disease.  Since the
Group's inception it has created a wide range of microbiome-based ingredients
and products including prebiotic products like SlimBiome®, WellBiome®,
SweetBiotix® and Microbiome Modulators within its core OptiBiotix Health plc
(OPTI) business, but also skincare through its holdings in SkinBioTherapeutics
PLC (SBTX), and probiotics through ProBiotix Health plc (PBX). These companies
create a diverse portfolio technologies and products in an emerging area of
healthcare that is of growing interest in consumer markets throughout the
world.

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUMPAUPQPUW



            Copyright 2019 Regulatory News Service, all rights reserved